AUGMENTIN '250' (amoxicillin; clavulanate potassium) by Pfizer. Approved for infections due to susceptible strains of designated microorganisms, the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus species, the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli and 3 more indications. First approved in 1984.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AUGMENTIN '250' is an oral fixed-dose combination of amoxicillin and clavulanate potassium, a β-lactam antibiotic with β-lactamase inhibitor. It treats infections caused by susceptible β-lactamase-negative gram-positive and gram-negative bacteria including Streptococcus species, E. coli, Proteus mirabilis, and Enterococcus faecalis. The clavulanate component protects amoxicillin from degradation by bacterial β-lactamases, restoring efficacy against resistant strains.
Product is in advanced decline phase with minimal linked job opportunities; commercial teams are likely consolidating and focused on managed transition rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on AUGMENTIN '250' at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on AUGMENTIN '250' offers limited career growth opportunity given the LOE-approaching lifecycle and zero linked job openings. Roles emphasize cost management, compliance, and managed decline rather than innovation or market expansion.